Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
Antonis C. Antoniou(Weatherford College), Tomasz Huzarski(International Hereditary Cancer Center), Giuseppe Giannini(Istituto Pasteur), Annika Lindblom(Karolinska University Hospital), Jan Lubiński(Tumour Institute of Tuscany), Hans Ehrencrona(Lund University), Valeria Pensotti(IFOM), Riccardo Dolcetti(Translational Research Institute), Eitan Friedman(University of Pennsylvania), Barbara Pasini(University of Turin), Siranoush Manoukian(Fondazione IRCCS Istituto Nazionale dei Tumori), Katja Harbst(Lund University), Liliana Varesco(Istituti di Ricovero e Cura a Carattere Scientifico), Bella Kaufman(NYU Langone Health), Irene L. Andrulis(University of Toronto), Anna Jakubowska(Pomeranian Medical University), Christiana Kartsonaki(University of Oxford), Gord Glendon(University Health Network), Daniela Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Susan M. Domchek(University City Science Center), Anna Laura Putignano(University of Modena and Reggio Emilia), Katherine L. Nathanson(Translational Therapeutics (United States)), Anne‐Marie Gerdes(Copenhagen University Hospital), Roni Milgrom(Sheba Medical Center), Beatrice Melin(Umeå University), Bernard Peissel(Sapienza University of Rome), Uffe Birk Jensen(Aarhus University Hospital), Mark H. Greene(Cancer Institute (WIA)), Jacek Gronwald(International Hereditary Cancer Center), Andrew Lee(University of Cambridge), Brita Arver(Karolinska University Hospital), Paolo Peterlongo(IFOM), Paolo Radice(IFOM), Monica Barile(European Institute of Oncology), Hilmi Özçelik(Mount Sinai Hospital), Yael Laitman(Sheba Medical Center), Lesley McGuffog(University of Cambridge), Torben A. Kruse(Odense University Hospital), Sue Healey(QIMR Berghofer Medical Research Institute), Timothy R. Rebbeck(University of Pennsylvania), Mads Thomassen(Odense University Hospital), Niklas Loman(Lund University), Penny Soucy(University of Cambridge), Dorthe Gylling Crüger(Vejle Sygehus), Olga M. Sinilnikova(Hospices Civils de Lyon), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Elisa Cattaneo(Fondazione IRCCS Istituto Nazionale dei Tumori), Shani Paluch–Shimon(Hebrew University of Jerusalem)
Cited by 77
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Cost of disorders of the brain in Europe 2010
|European Neuropsychopharmacology|2011|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k